J INFLAMM RES 润色咨询

Journal of Inflammation Research

出版年份：暂无数据 年文章数：1027 投稿命中率： 开通期刊会员，数据随心看

出版周期：C 自引率：暂无数据 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2256447, encodeId=e067225644eb7, content= <br>1AB会持续多久 已经投稿半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dba02798280, createdName=luozf2013, createdTime=Mon Mar 17 15:16:58 CST 2025, time=昨天, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254847, encodeId=f383225484e2f, content=偏重的研究方向：免疫;炎症<br>经验分享：2g和2g x有啥区别？？2g x是拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19302219324, createdName=120f50f1m32(暂无昵称), createdTime=Thu Mar 06 12:03:22 CST 2025, time=2025-03-06, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2255761, encodeId=adac2255e6167, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：看了论坛好久，今天回馈给兄弟们一个时间线<br>12 December 2024 Peer review selection<br>13 December 2024 Peer review invitations sent<br>13 December 2024 First peer reviewer allocated<br>2 January 2025 First report returned<br>22 January 2025 Second or more peer reviewer reports returned<br>22 January 2025 Report sent to the Editor-in-Chief<br>24 January 2025 Report: revise with changes<br>31 January 2025 Resubmission pending<br>6 February 2025 Resubmitted manuscript received<br>13 February 2025 Query regarding revised manuscript<br>15 February 2025 Processing revised manuscript<br>21 February 2025 Sent to Editor-in-Chief for acceptance or rejection<br>21 February 2025 Peer reviewer(s) second round<br>3 March 2025 Peer reviewer(s) second round completed<br>March 2025 Accepted for publication, invoice sent<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9fa5603307, createdName=ms2000002102678296, createdTime=Wed Mar 12 16:28:46 CST 2025, time=2025-03-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218136, encodeId=09a322181369e, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：2024-03-12 submitted 之后一直1A_1<br>2024-04-04 变成了1A_2 然后继续没动静。。。<br>2024-05-02 收到编辑邮件让确认一篇团队刚发表的文章，说重复性高，回复后让添加到参考文献。<br>2024-05-06 重新提交后让每位作者确认利益冲突<br>2024-05-07 送审<br>2024-06-27 Report sent to the Editor-in-Chief<br>2024-07-02 Report: revise with changes 但是7-5才收到编辑让修稿及具体审稿意见的邮件<br>2024-07-19 Resubmitted manuscript received<br>2024-07-24 Sent to Editor-in-Chief for acceptance or rejection<br>2024-07-30 Accepted for publication, invoice sent<br>前期真的巨无敌慢！！！着急毕业的慎重。期间发了无数条邮件问，好在编辑回复的还算及时。<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e62d5561724, createdName=duanduan127, createdTime=Fri Aug 02 14:51:42 CST 2024, time=2024-08-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254749, encodeId=c3052254e4945, content=审稿速度:3.0<br>经验分享：7I是什么意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Wed Mar 05 18:10:41 CST 2025, time=2025-03-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2202091, encodeId=4ba42202091a9, content=4CX直接到7i是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ee74781933, createdName=gujianjun, createdTime=Mon May 06 22:51:00 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254635, encodeId=d6922254635b6, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：皮肤科;炎症<br>经验分享：2024-11-28 04:27:20 Manuscript submitted to Dove Medical Press<br>2024-12-10 14:10:57 Manuscript submitted to Journal of Inflammation Research <br>2024-12-24 00:40:42 Submission to Journal of Inflammation Research <br>2024-12-30 21:59:06 Manuscript Update Journal of Inflammation Research [Sub ID 509089]<br>2025-01-08 09:52:36 Your manuscript has been sent to the Editor-in-Chief <br>2025-01-21 18:26:52 Dove Medical Press - Confirmation of Revision Acceptance<br>2025-02-05 05:51:12 Your revised files have been successfully submitted<br>2025-02-19 22:08:16 Your corrected files have been successfully submitted [ID: 509089]<br>2025-02-26 16:49:58 Your manuscript has been sent to the Editor-in-Chief<br>2025-03-04 11:12:25 Dove Medical Press: Submission accepted for publication, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=013c8364030, createdName=ms9000000148815301, createdTime=Wed Mar 05 02:23:48 CST 2025, time=2025-03-05, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2254323, encodeId=c08f2254323e6, content=偏重的研究方向：炎症<br>经验分享：我想问一下大家二轮审稿是什么时候回来的呀？呜呜呜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Mon Mar 03 08:20:28 CST 2025, time=2025-03-03, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2247760, encodeId=14b7224e76081, content=审稿速度:1.0<br>偏重的研究方向：骨科<br>经验分享：投稿速度出奇的快，真是太震惊了，去年十月底投稿<br>1.10日就录用，总共经历了2两轮审稿，太给力了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:15:14 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251451, encodeId=3900225145188, content=偏重的研究方向：肿瘤<br>经验分享：请问4cr二轮审稿 多久会有结果呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Feb 11 14:00:04 CST 2025, time=2025-02-11, status=1, ipAttribution=上海)]
    昨天 luozf2013 来自河南省


    1AB会持续多久 已经投稿半个月了

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2256447, encodeId=e067225644eb7, content= <br>1AB会持续多久 已经投稿半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dba02798280, createdName=luozf2013, createdTime=Mon Mar 17 15:16:58 CST 2025, time=昨天, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254847, encodeId=f383225484e2f, content=偏重的研究方向：免疫;炎症<br>经验分享：2g和2g x有啥区别？？2g x是拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19302219324, createdName=120f50f1m32(暂无昵称), createdTime=Thu Mar 06 12:03:22 CST 2025, time=2025-03-06, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2255761, encodeId=adac2255e6167, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：看了论坛好久，今天回馈给兄弟们一个时间线<br>12 December 2024 Peer review selection<br>13 December 2024 Peer review invitations sent<br>13 December 2024 First peer reviewer allocated<br>2 January 2025 First report returned<br>22 January 2025 Second or more peer reviewer reports returned<br>22 January 2025 Report sent to the Editor-in-Chief<br>24 January 2025 Report: revise with changes<br>31 January 2025 Resubmission pending<br>6 February 2025 Resubmitted manuscript received<br>13 February 2025 Query regarding revised manuscript<br>15 February 2025 Processing revised manuscript<br>21 February 2025 Sent to Editor-in-Chief for acceptance or rejection<br>21 February 2025 Peer reviewer(s) second round<br>3 March 2025 Peer reviewer(s) second round completed<br>March 2025 Accepted for publication, invoice sent<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9fa5603307, createdName=ms2000002102678296, createdTime=Wed Mar 12 16:28:46 CST 2025, time=2025-03-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218136, encodeId=09a322181369e, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：2024-03-12 submitted 之后一直1A_1<br>2024-04-04 变成了1A_2 然后继续没动静。。。<br>2024-05-02 收到编辑邮件让确认一篇团队刚发表的文章，说重复性高，回复后让添加到参考文献。<br>2024-05-06 重新提交后让每位作者确认利益冲突<br>2024-05-07 送审<br>2024-06-27 Report sent to the Editor-in-Chief<br>2024-07-02 Report: revise with changes 但是7-5才收到编辑让修稿及具体审稿意见的邮件<br>2024-07-19 Resubmitted manuscript received<br>2024-07-24 Sent to Editor-in-Chief for acceptance or rejection<br>2024-07-30 Accepted for publication, invoice sent<br>前期真的巨无敌慢！！！着急毕业的慎重。期间发了无数条邮件问，好在编辑回复的还算及时。<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e62d5561724, createdName=duanduan127, createdTime=Fri Aug 02 14:51:42 CST 2024, time=2024-08-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254749, encodeId=c3052254e4945, content=审稿速度:3.0<br>经验分享：7I是什么意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Wed Mar 05 18:10:41 CST 2025, time=2025-03-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2202091, encodeId=4ba42202091a9, content=4CX直接到7i是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ee74781933, createdName=gujianjun, createdTime=Mon May 06 22:51:00 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254635, encodeId=d6922254635b6, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：皮肤科;炎症<br>经验分享：2024-11-28 04:27:20 Manuscript submitted to Dove Medical Press<br>2024-12-10 14:10:57 Manuscript submitted to Journal of Inflammation Research <br>2024-12-24 00:40:42 Submission to Journal of Inflammation Research <br>2024-12-30 21:59:06 Manuscript Update Journal of Inflammation Research [Sub ID 509089]<br>2025-01-08 09:52:36 Your manuscript has been sent to the Editor-in-Chief <br>2025-01-21 18:26:52 Dove Medical Press - Confirmation of Revision Acceptance<br>2025-02-05 05:51:12 Your revised files have been successfully submitted<br>2025-02-19 22:08:16 Your corrected files have been successfully submitted [ID: 509089]<br>2025-02-26 16:49:58 Your manuscript has been sent to the Editor-in-Chief<br>2025-03-04 11:12:25 Dove Medical Press: Submission accepted for publication, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=013c8364030, createdName=ms9000000148815301, createdTime=Wed Mar 05 02:23:48 CST 2025, time=2025-03-05, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2254323, encodeId=c08f2254323e6, content=偏重的研究方向：炎症<br>经验分享：我想问一下大家二轮审稿是什么时候回来的呀？呜呜呜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Mon Mar 03 08:20:28 CST 2025, time=2025-03-03, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2247760, encodeId=14b7224e76081, content=审稿速度:1.0<br>偏重的研究方向：骨科<br>经验分享：投稿速度出奇的快，真是太震惊了，去年十月底投稿<br>1.10日就录用，总共经历了2两轮审稿，太给力了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:15:14 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251451, encodeId=3900225145188, content=偏重的研究方向：肿瘤<br>经验分享：请问4cr二轮审稿 多久会有结果呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Feb 11 14:00:04 CST 2025, time=2025-02-11, status=1, ipAttribution=上海)]
    2025-03-06 120f50f1m32(暂无昵称) 来自安徽省

    偏重的研究方向：免疫;炎症
    经验分享：2g和2g x有啥区别？？2g x是拒稿吗？

    6

    展开6条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2256447, encodeId=e067225644eb7, content= <br>1AB会持续多久 已经投稿半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dba02798280, createdName=luozf2013, createdTime=Mon Mar 17 15:16:58 CST 2025, time=昨天, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254847, encodeId=f383225484e2f, content=偏重的研究方向：免疫;炎症<br>经验分享：2g和2g x有啥区别？？2g x是拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19302219324, createdName=120f50f1m32(暂无昵称), createdTime=Thu Mar 06 12:03:22 CST 2025, time=2025-03-06, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2255761, encodeId=adac2255e6167, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：看了论坛好久，今天回馈给兄弟们一个时间线<br>12 December 2024 Peer review selection<br>13 December 2024 Peer review invitations sent<br>13 December 2024 First peer reviewer allocated<br>2 January 2025 First report returned<br>22 January 2025 Second or more peer reviewer reports returned<br>22 January 2025 Report sent to the Editor-in-Chief<br>24 January 2025 Report: revise with changes<br>31 January 2025 Resubmission pending<br>6 February 2025 Resubmitted manuscript received<br>13 February 2025 Query regarding revised manuscript<br>15 February 2025 Processing revised manuscript<br>21 February 2025 Sent to Editor-in-Chief for acceptance or rejection<br>21 February 2025 Peer reviewer(s) second round<br>3 March 2025 Peer reviewer(s) second round completed<br>March 2025 Accepted for publication, invoice sent<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9fa5603307, createdName=ms2000002102678296, createdTime=Wed Mar 12 16:28:46 CST 2025, time=2025-03-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218136, encodeId=09a322181369e, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：2024-03-12 submitted 之后一直1A_1<br>2024-04-04 变成了1A_2 然后继续没动静。。。<br>2024-05-02 收到编辑邮件让确认一篇团队刚发表的文章，说重复性高，回复后让添加到参考文献。<br>2024-05-06 重新提交后让每位作者确认利益冲突<br>2024-05-07 送审<br>2024-06-27 Report sent to the Editor-in-Chief<br>2024-07-02 Report: revise with changes 但是7-5才收到编辑让修稿及具体审稿意见的邮件<br>2024-07-19 Resubmitted manuscript received<br>2024-07-24 Sent to Editor-in-Chief for acceptance or rejection<br>2024-07-30 Accepted for publication, invoice sent<br>前期真的巨无敌慢！！！着急毕业的慎重。期间发了无数条邮件问，好在编辑回复的还算及时。<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e62d5561724, createdName=duanduan127, createdTime=Fri Aug 02 14:51:42 CST 2024, time=2024-08-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254749, encodeId=c3052254e4945, content=审稿速度:3.0<br>经验分享：7I是什么意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Wed Mar 05 18:10:41 CST 2025, time=2025-03-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2202091, encodeId=4ba42202091a9, content=4CX直接到7i是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ee74781933, createdName=gujianjun, createdTime=Mon May 06 22:51:00 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254635, encodeId=d6922254635b6, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：皮肤科;炎症<br>经验分享：2024-11-28 04:27:20 Manuscript submitted to Dove Medical Press<br>2024-12-10 14:10:57 Manuscript submitted to Journal of Inflammation Research <br>2024-12-24 00:40:42 Submission to Journal of Inflammation Research <br>2024-12-30 21:59:06 Manuscript Update Journal of Inflammation Research [Sub ID 509089]<br>2025-01-08 09:52:36 Your manuscript has been sent to the Editor-in-Chief <br>2025-01-21 18:26:52 Dove Medical Press - Confirmation of Revision Acceptance<br>2025-02-05 05:51:12 Your revised files have been successfully submitted<br>2025-02-19 22:08:16 Your corrected files have been successfully submitted [ID: 509089]<br>2025-02-26 16:49:58 Your manuscript has been sent to the Editor-in-Chief<br>2025-03-04 11:12:25 Dove Medical Press: Submission accepted for publication, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=013c8364030, createdName=ms9000000148815301, createdTime=Wed Mar 05 02:23:48 CST 2025, time=2025-03-05, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2254323, encodeId=c08f2254323e6, content=偏重的研究方向：炎症<br>经验分享：我想问一下大家二轮审稿是什么时候回来的呀？呜呜呜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Mon Mar 03 08:20:28 CST 2025, time=2025-03-03, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2247760, encodeId=14b7224e76081, content=审稿速度:1.0<br>偏重的研究方向：骨科<br>经验分享：投稿速度出奇的快，真是太震惊了，去年十月底投稿<br>1.10日就录用，总共经历了2两轮审稿，太给力了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:15:14 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251451, encodeId=3900225145188, content=偏重的研究方向：肿瘤<br>经验分享：请问4cr二轮审稿 多久会有结果呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Feb 11 14:00:04 CST 2025, time=2025-02-11, status=1, ipAttribution=上海)]
    2025-03-12 ms2000002102678296 来自广东省

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享：看了论坛好久，今天回馈给兄弟们一个时间线
    12 December 2024 Peer review selection
    13 December 2024 Peer review invitations sent
    13 December 2024 First peer reviewer allocated
    2 January 2025 First report returned
    22 January 2025 Second or more peer reviewer reports returned
    22 January 2025 Report sent to the Editor-in-Chief
    24 January 2025 Report: revise with changes
    31 January 2025 Resubmission pending
    6 February 2025 Resubmitted manuscript received
    13 February 2025 Query regarding revised manuscript
    15 February 2025 Processing revised manuscript
    21 February 2025 Sent to Editor-in-Chief for acceptance or rejection
    21 February 2025 Peer reviewer(s) second round
    3 March 2025 Peer reviewer(s) second round completed
    March 2025 Accepted for publication, invoice sent


    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2256447, encodeId=e067225644eb7, content= <br>1AB会持续多久 已经投稿半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dba02798280, createdName=luozf2013, createdTime=Mon Mar 17 15:16:58 CST 2025, time=昨天, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254847, encodeId=f383225484e2f, content=偏重的研究方向：免疫;炎症<br>经验分享：2g和2g x有啥区别？？2g x是拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19302219324, createdName=120f50f1m32(暂无昵称), createdTime=Thu Mar 06 12:03:22 CST 2025, time=2025-03-06, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2255761, encodeId=adac2255e6167, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：看了论坛好久，今天回馈给兄弟们一个时间线<br>12 December 2024 Peer review selection<br>13 December 2024 Peer review invitations sent<br>13 December 2024 First peer reviewer allocated<br>2 January 2025 First report returned<br>22 January 2025 Second or more peer reviewer reports returned<br>22 January 2025 Report sent to the Editor-in-Chief<br>24 January 2025 Report: revise with changes<br>31 January 2025 Resubmission pending<br>6 February 2025 Resubmitted manuscript received<br>13 February 2025 Query regarding revised manuscript<br>15 February 2025 Processing revised manuscript<br>21 February 2025 Sent to Editor-in-Chief for acceptance or rejection<br>21 February 2025 Peer reviewer(s) second round<br>3 March 2025 Peer reviewer(s) second round completed<br>March 2025 Accepted for publication, invoice sent<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9fa5603307, createdName=ms2000002102678296, createdTime=Wed Mar 12 16:28:46 CST 2025, time=2025-03-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218136, encodeId=09a322181369e, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：2024-03-12 submitted 之后一直1A_1<br>2024-04-04 变成了1A_2 然后继续没动静。。。<br>2024-05-02 收到编辑邮件让确认一篇团队刚发表的文章，说重复性高，回复后让添加到参考文献。<br>2024-05-06 重新提交后让每位作者确认利益冲突<br>2024-05-07 送审<br>2024-06-27 Report sent to the Editor-in-Chief<br>2024-07-02 Report: revise with changes 但是7-5才收到编辑让修稿及具体审稿意见的邮件<br>2024-07-19 Resubmitted manuscript received<br>2024-07-24 Sent to Editor-in-Chief for acceptance or rejection<br>2024-07-30 Accepted for publication, invoice sent<br>前期真的巨无敌慢！！！着急毕业的慎重。期间发了无数条邮件问，好在编辑回复的还算及时。<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e62d5561724, createdName=duanduan127, createdTime=Fri Aug 02 14:51:42 CST 2024, time=2024-08-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254749, encodeId=c3052254e4945, content=审稿速度:3.0<br>经验分享：7I是什么意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Wed Mar 05 18:10:41 CST 2025, time=2025-03-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2202091, encodeId=4ba42202091a9, content=4CX直接到7i是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ee74781933, createdName=gujianjun, createdTime=Mon May 06 22:51:00 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254635, encodeId=d6922254635b6, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：皮肤科;炎症<br>经验分享：2024-11-28 04:27:20 Manuscript submitted to Dove Medical Press<br>2024-12-10 14:10:57 Manuscript submitted to Journal of Inflammation Research <br>2024-12-24 00:40:42 Submission to Journal of Inflammation Research <br>2024-12-30 21:59:06 Manuscript Update Journal of Inflammation Research [Sub ID 509089]<br>2025-01-08 09:52:36 Your manuscript has been sent to the Editor-in-Chief <br>2025-01-21 18:26:52 Dove Medical Press - Confirmation of Revision Acceptance<br>2025-02-05 05:51:12 Your revised files have been successfully submitted<br>2025-02-19 22:08:16 Your corrected files have been successfully submitted [ID: 509089]<br>2025-02-26 16:49:58 Your manuscript has been sent to the Editor-in-Chief<br>2025-03-04 11:12:25 Dove Medical Press: Submission accepted for publication, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=013c8364030, createdName=ms9000000148815301, createdTime=Wed Mar 05 02:23:48 CST 2025, time=2025-03-05, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2254323, encodeId=c08f2254323e6, content=偏重的研究方向：炎症<br>经验分享：我想问一下大家二轮审稿是什么时候回来的呀？呜呜呜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Mon Mar 03 08:20:28 CST 2025, time=2025-03-03, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2247760, encodeId=14b7224e76081, content=审稿速度:1.0<br>偏重的研究方向：骨科<br>经验分享：投稿速度出奇的快，真是太震惊了，去年十月底投稿<br>1.10日就录用，总共经历了2两轮审稿，太给力了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:15:14 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251451, encodeId=3900225145188, content=偏重的研究方向：肿瘤<br>经验分享：请问4cr二轮审稿 多久会有结果呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Feb 11 14:00:04 CST 2025, time=2025-02-11, status=1, ipAttribution=上海)]
    2024-08-02 duanduan127 来自北京

    审稿速度:2.0 | 投稿命中率:75.0
    经验分享：2024-03-12 submitted 之后一直1A_1
    2024-04-04 变成了1A_2 然后继续没动静。。。
    2024-05-02 收到编辑邮件让确认一篇团队刚发表的文章，说重复性高，回复后让添加到参考文献。
    2024-05-06 重新提交后让每位作者确认利益冲突
    2024-05-07 送审
    2024-06-27 Report sent to the Editor-in-Chief
    2024-07-02 Report: revise with changes 但是7-5才收到编辑让修稿及具体审稿意见的邮件
    2024-07-19 Resubmitted manuscript received
    2024-07-24 Sent to Editor-in-Chief for acceptance or rejection
    2024-07-30 Accepted for publication, invoice sent
    前期真的巨无敌慢！！！着急毕业的慎重。期间发了无数条邮件问，好在编辑回复的还算及时。


    5

    展开5条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2256447, encodeId=e067225644eb7, content= <br>1AB会持续多久 已经投稿半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dba02798280, createdName=luozf2013, createdTime=Mon Mar 17 15:16:58 CST 2025, time=昨天, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254847, encodeId=f383225484e2f, content=偏重的研究方向：免疫;炎症<br>经验分享：2g和2g x有啥区别？？2g x是拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19302219324, createdName=120f50f1m32(暂无昵称), createdTime=Thu Mar 06 12:03:22 CST 2025, time=2025-03-06, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2255761, encodeId=adac2255e6167, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：看了论坛好久，今天回馈给兄弟们一个时间线<br>12 December 2024 Peer review selection<br>13 December 2024 Peer review invitations sent<br>13 December 2024 First peer reviewer allocated<br>2 January 2025 First report returned<br>22 January 2025 Second or more peer reviewer reports returned<br>22 January 2025 Report sent to the Editor-in-Chief<br>24 January 2025 Report: revise with changes<br>31 January 2025 Resubmission pending<br>6 February 2025 Resubmitted manuscript received<br>13 February 2025 Query regarding revised manuscript<br>15 February 2025 Processing revised manuscript<br>21 February 2025 Sent to Editor-in-Chief for acceptance or rejection<br>21 February 2025 Peer reviewer(s) second round<br>3 March 2025 Peer reviewer(s) second round completed<br>March 2025 Accepted for publication, invoice sent<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9fa5603307, createdName=ms2000002102678296, createdTime=Wed Mar 12 16:28:46 CST 2025, time=2025-03-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218136, encodeId=09a322181369e, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：2024-03-12 submitted 之后一直1A_1<br>2024-04-04 变成了1A_2 然后继续没动静。。。<br>2024-05-02 收到编辑邮件让确认一篇团队刚发表的文章，说重复性高，回复后让添加到参考文献。<br>2024-05-06 重新提交后让每位作者确认利益冲突<br>2024-05-07 送审<br>2024-06-27 Report sent to the Editor-in-Chief<br>2024-07-02 Report: revise with changes 但是7-5才收到编辑让修稿及具体审稿意见的邮件<br>2024-07-19 Resubmitted manuscript received<br>2024-07-24 Sent to Editor-in-Chief for acceptance or rejection<br>2024-07-30 Accepted for publication, invoice sent<br>前期真的巨无敌慢！！！着急毕业的慎重。期间发了无数条邮件问，好在编辑回复的还算及时。<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e62d5561724, createdName=duanduan127, createdTime=Fri Aug 02 14:51:42 CST 2024, time=2024-08-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254749, encodeId=c3052254e4945, content=审稿速度:3.0<br>经验分享：7I是什么意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Wed Mar 05 18:10:41 CST 2025, time=2025-03-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2202091, encodeId=4ba42202091a9, content=4CX直接到7i是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ee74781933, createdName=gujianjun, createdTime=Mon May 06 22:51:00 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254635, encodeId=d6922254635b6, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：皮肤科;炎症<br>经验分享：2024-11-28 04:27:20 Manuscript submitted to Dove Medical Press<br>2024-12-10 14:10:57 Manuscript submitted to Journal of Inflammation Research <br>2024-12-24 00:40:42 Submission to Journal of Inflammation Research <br>2024-12-30 21:59:06 Manuscript Update Journal of Inflammation Research [Sub ID 509089]<br>2025-01-08 09:52:36 Your manuscript has been sent to the Editor-in-Chief <br>2025-01-21 18:26:52 Dove Medical Press - Confirmation of Revision Acceptance<br>2025-02-05 05:51:12 Your revised files have been successfully submitted<br>2025-02-19 22:08:16 Your corrected files have been successfully submitted [ID: 509089]<br>2025-02-26 16:49:58 Your manuscript has been sent to the Editor-in-Chief<br>2025-03-04 11:12:25 Dove Medical Press: Submission accepted for publication, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=013c8364030, createdName=ms9000000148815301, createdTime=Wed Mar 05 02:23:48 CST 2025, time=2025-03-05, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2254323, encodeId=c08f2254323e6, content=偏重的研究方向：炎症<br>经验分享：我想问一下大家二轮审稿是什么时候回来的呀？呜呜呜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Mon Mar 03 08:20:28 CST 2025, time=2025-03-03, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2247760, encodeId=14b7224e76081, content=审稿速度:1.0<br>偏重的研究方向：骨科<br>经验分享：投稿速度出奇的快，真是太震惊了，去年十月底投稿<br>1.10日就录用，总共经历了2两轮审稿，太给力了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:15:14 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251451, encodeId=3900225145188, content=偏重的研究方向：肿瘤<br>经验分享：请问4cr二轮审稿 多久会有结果呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Feb 11 14:00:04 CST 2025, time=2025-02-11, status=1, ipAttribution=上海)]
    2025-03-05 ms8000000556081062 来自甘肃省

    审稿速度:3.0
    经验分享：7I是什么意思啊

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2256447, encodeId=e067225644eb7, content= <br>1AB会持续多久 已经投稿半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dba02798280, createdName=luozf2013, createdTime=Mon Mar 17 15:16:58 CST 2025, time=昨天, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254847, encodeId=f383225484e2f, content=偏重的研究方向：免疫;炎症<br>经验分享：2g和2g x有啥区别？？2g x是拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19302219324, createdName=120f50f1m32(暂无昵称), createdTime=Thu Mar 06 12:03:22 CST 2025, time=2025-03-06, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2255761, encodeId=adac2255e6167, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：看了论坛好久，今天回馈给兄弟们一个时间线<br>12 December 2024 Peer review selection<br>13 December 2024 Peer review invitations sent<br>13 December 2024 First peer reviewer allocated<br>2 January 2025 First report returned<br>22 January 2025 Second or more peer reviewer reports returned<br>22 January 2025 Report sent to the Editor-in-Chief<br>24 January 2025 Report: revise with changes<br>31 January 2025 Resubmission pending<br>6 February 2025 Resubmitted manuscript received<br>13 February 2025 Query regarding revised manuscript<br>15 February 2025 Processing revised manuscript<br>21 February 2025 Sent to Editor-in-Chief for acceptance or rejection<br>21 February 2025 Peer reviewer(s) second round<br>3 March 2025 Peer reviewer(s) second round completed<br>March 2025 Accepted for publication, invoice sent<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9fa5603307, createdName=ms2000002102678296, createdTime=Wed Mar 12 16:28:46 CST 2025, time=2025-03-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218136, encodeId=09a322181369e, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：2024-03-12 submitted 之后一直1A_1<br>2024-04-04 变成了1A_2 然后继续没动静。。。<br>2024-05-02 收到编辑邮件让确认一篇团队刚发表的文章，说重复性高，回复后让添加到参考文献。<br>2024-05-06 重新提交后让每位作者确认利益冲突<br>2024-05-07 送审<br>2024-06-27 Report sent to the Editor-in-Chief<br>2024-07-02 Report: revise with changes 但是7-5才收到编辑让修稿及具体审稿意见的邮件<br>2024-07-19 Resubmitted manuscript received<br>2024-07-24 Sent to Editor-in-Chief for acceptance or rejection<br>2024-07-30 Accepted for publication, invoice sent<br>前期真的巨无敌慢！！！着急毕业的慎重。期间发了无数条邮件问，好在编辑回复的还算及时。<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e62d5561724, createdName=duanduan127, createdTime=Fri Aug 02 14:51:42 CST 2024, time=2024-08-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254749, encodeId=c3052254e4945, content=审稿速度:3.0<br>经验分享：7I是什么意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Wed Mar 05 18:10:41 CST 2025, time=2025-03-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2202091, encodeId=4ba42202091a9, content=4CX直接到7i是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ee74781933, createdName=gujianjun, createdTime=Mon May 06 22:51:00 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254635, encodeId=d6922254635b6, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：皮肤科;炎症<br>经验分享：2024-11-28 04:27:20 Manuscript submitted to Dove Medical Press<br>2024-12-10 14:10:57 Manuscript submitted to Journal of Inflammation Research <br>2024-12-24 00:40:42 Submission to Journal of Inflammation Research <br>2024-12-30 21:59:06 Manuscript Update Journal of Inflammation Research [Sub ID 509089]<br>2025-01-08 09:52:36 Your manuscript has been sent to the Editor-in-Chief <br>2025-01-21 18:26:52 Dove Medical Press - Confirmation of Revision Acceptance<br>2025-02-05 05:51:12 Your revised files have been successfully submitted<br>2025-02-19 22:08:16 Your corrected files have been successfully submitted [ID: 509089]<br>2025-02-26 16:49:58 Your manuscript has been sent to the Editor-in-Chief<br>2025-03-04 11:12:25 Dove Medical Press: Submission accepted for publication, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=013c8364030, createdName=ms9000000148815301, createdTime=Wed Mar 05 02:23:48 CST 2025, time=2025-03-05, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2254323, encodeId=c08f2254323e6, content=偏重的研究方向：炎症<br>经验分享：我想问一下大家二轮审稿是什么时候回来的呀？呜呜呜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Mon Mar 03 08:20:28 CST 2025, time=2025-03-03, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2247760, encodeId=14b7224e76081, content=审稿速度:1.0<br>偏重的研究方向：骨科<br>经验分享：投稿速度出奇的快，真是太震惊了，去年十月底投稿<br>1.10日就录用，总共经历了2两轮审稿，太给力了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:15:14 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251451, encodeId=3900225145188, content=偏重的研究方向：肿瘤<br>经验分享：请问4cr二轮审稿 多久会有结果呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Feb 11 14:00:04 CST 2025, time=2025-02-11, status=1, ipAttribution=上海)]
    2024-05-06 gujianjun 来自河南省

    4CX直接到7i是不是要被拒稿了？

    4

    展开4条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2256447, encodeId=e067225644eb7, content= <br>1AB会持续多久 已经投稿半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dba02798280, createdName=luozf2013, createdTime=Mon Mar 17 15:16:58 CST 2025, time=昨天, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254847, encodeId=f383225484e2f, content=偏重的研究方向：免疫;炎症<br>经验分享：2g和2g x有啥区别？？2g x是拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19302219324, createdName=120f50f1m32(暂无昵称), createdTime=Thu Mar 06 12:03:22 CST 2025, time=2025-03-06, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2255761, encodeId=adac2255e6167, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：看了论坛好久，今天回馈给兄弟们一个时间线<br>12 December 2024 Peer review selection<br>13 December 2024 Peer review invitations sent<br>13 December 2024 First peer reviewer allocated<br>2 January 2025 First report returned<br>22 January 2025 Second or more peer reviewer reports returned<br>22 January 2025 Report sent to the Editor-in-Chief<br>24 January 2025 Report: revise with changes<br>31 January 2025 Resubmission pending<br>6 February 2025 Resubmitted manuscript received<br>13 February 2025 Query regarding revised manuscript<br>15 February 2025 Processing revised manuscript<br>21 February 2025 Sent to Editor-in-Chief for acceptance or rejection<br>21 February 2025 Peer reviewer(s) second round<br>3 March 2025 Peer reviewer(s) second round completed<br>March 2025 Accepted for publication, invoice sent<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9fa5603307, createdName=ms2000002102678296, createdTime=Wed Mar 12 16:28:46 CST 2025, time=2025-03-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218136, encodeId=09a322181369e, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：2024-03-12 submitted 之后一直1A_1<br>2024-04-04 变成了1A_2 然后继续没动静。。。<br>2024-05-02 收到编辑邮件让确认一篇团队刚发表的文章，说重复性高，回复后让添加到参考文献。<br>2024-05-06 重新提交后让每位作者确认利益冲突<br>2024-05-07 送审<br>2024-06-27 Report sent to the Editor-in-Chief<br>2024-07-02 Report: revise with changes 但是7-5才收到编辑让修稿及具体审稿意见的邮件<br>2024-07-19 Resubmitted manuscript received<br>2024-07-24 Sent to Editor-in-Chief for acceptance or rejection<br>2024-07-30 Accepted for publication, invoice sent<br>前期真的巨无敌慢！！！着急毕业的慎重。期间发了无数条邮件问，好在编辑回复的还算及时。<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e62d5561724, createdName=duanduan127, createdTime=Fri Aug 02 14:51:42 CST 2024, time=2024-08-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254749, encodeId=c3052254e4945, content=审稿速度:3.0<br>经验分享：7I是什么意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Wed Mar 05 18:10:41 CST 2025, time=2025-03-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2202091, encodeId=4ba42202091a9, content=4CX直接到7i是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ee74781933, createdName=gujianjun, createdTime=Mon May 06 22:51:00 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254635, encodeId=d6922254635b6, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：皮肤科;炎症<br>经验分享：2024-11-28 04:27:20 Manuscript submitted to Dove Medical Press<br>2024-12-10 14:10:57 Manuscript submitted to Journal of Inflammation Research <br>2024-12-24 00:40:42 Submission to Journal of Inflammation Research <br>2024-12-30 21:59:06 Manuscript Update Journal of Inflammation Research [Sub ID 509089]<br>2025-01-08 09:52:36 Your manuscript has been sent to the Editor-in-Chief <br>2025-01-21 18:26:52 Dove Medical Press - Confirmation of Revision Acceptance<br>2025-02-05 05:51:12 Your revised files have been successfully submitted<br>2025-02-19 22:08:16 Your corrected files have been successfully submitted [ID: 509089]<br>2025-02-26 16:49:58 Your manuscript has been sent to the Editor-in-Chief<br>2025-03-04 11:12:25 Dove Medical Press: Submission accepted for publication, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=013c8364030, createdName=ms9000000148815301, createdTime=Wed Mar 05 02:23:48 CST 2025, time=2025-03-05, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2254323, encodeId=c08f2254323e6, content=偏重的研究方向：炎症<br>经验分享：我想问一下大家二轮审稿是什么时候回来的呀？呜呜呜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Mon Mar 03 08:20:28 CST 2025, time=2025-03-03, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2247760, encodeId=14b7224e76081, content=审稿速度:1.0<br>偏重的研究方向：骨科<br>经验分享：投稿速度出奇的快，真是太震惊了，去年十月底投稿<br>1.10日就录用，总共经历了2两轮审稿，太给力了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:15:14 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251451, encodeId=3900225145188, content=偏重的研究方向：肿瘤<br>经验分享：请问4cr二轮审稿 多久会有结果呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Feb 11 14:00:04 CST 2025, time=2025-02-11, status=1, ipAttribution=上海)]
    2025-03-05 ms9000000148815301 来自伊利诺伊

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向：皮肤科;炎症
    经验分享：2024-11-28 04:27:20 Manuscript submitted to Dove Medical Press
    2024-12-10 14:10:57 Manuscript submitted to Journal of Inflammation Research
    2024-12-24 00:40:42 Submission to Journal of Inflammation Research
    2024-12-30 21:59:06 Manuscript Update Journal of Inflammation Research [Sub ID 509089]
    2025-01-08 09:52:36 Your manuscript has been sent to the Editor-in-Chief
    2025-01-21 18:26:52 Dove Medical Press - Confirmation of Revision Acceptance
    2025-02-05 05:51:12 Your revised files have been successfully submitted
    2025-02-19 22:08:16 Your corrected files have been successfully submitted [ID: 509089]
    2025-02-26 16:49:58 Your manuscript has been sent to the Editor-in-Chief
    2025-03-04 11:12:25 Dove Medical Press: Submission accepted for publication

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2256447, encodeId=e067225644eb7, content= <br>1AB会持续多久 已经投稿半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dba02798280, createdName=luozf2013, createdTime=Mon Mar 17 15:16:58 CST 2025, time=昨天, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254847, encodeId=f383225484e2f, content=偏重的研究方向：免疫;炎症<br>经验分享：2g和2g x有啥区别？？2g x是拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19302219324, createdName=120f50f1m32(暂无昵称), createdTime=Thu Mar 06 12:03:22 CST 2025, time=2025-03-06, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2255761, encodeId=adac2255e6167, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：看了论坛好久，今天回馈给兄弟们一个时间线<br>12 December 2024 Peer review selection<br>13 December 2024 Peer review invitations sent<br>13 December 2024 First peer reviewer allocated<br>2 January 2025 First report returned<br>22 January 2025 Second or more peer reviewer reports returned<br>22 January 2025 Report sent to the Editor-in-Chief<br>24 January 2025 Report: revise with changes<br>31 January 2025 Resubmission pending<br>6 February 2025 Resubmitted manuscript received<br>13 February 2025 Query regarding revised manuscript<br>15 February 2025 Processing revised manuscript<br>21 February 2025 Sent to Editor-in-Chief for acceptance or rejection<br>21 February 2025 Peer reviewer(s) second round<br>3 March 2025 Peer reviewer(s) second round completed<br>March 2025 Accepted for publication, invoice sent<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9fa5603307, createdName=ms2000002102678296, createdTime=Wed Mar 12 16:28:46 CST 2025, time=2025-03-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218136, encodeId=09a322181369e, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：2024-03-12 submitted 之后一直1A_1<br>2024-04-04 变成了1A_2 然后继续没动静。。。<br>2024-05-02 收到编辑邮件让确认一篇团队刚发表的文章，说重复性高，回复后让添加到参考文献。<br>2024-05-06 重新提交后让每位作者确认利益冲突<br>2024-05-07 送审<br>2024-06-27 Report sent to the Editor-in-Chief<br>2024-07-02 Report: revise with changes 但是7-5才收到编辑让修稿及具体审稿意见的邮件<br>2024-07-19 Resubmitted manuscript received<br>2024-07-24 Sent to Editor-in-Chief for acceptance or rejection<br>2024-07-30 Accepted for publication, invoice sent<br>前期真的巨无敌慢！！！着急毕业的慎重。期间发了无数条邮件问，好在编辑回复的还算及时。<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e62d5561724, createdName=duanduan127, createdTime=Fri Aug 02 14:51:42 CST 2024, time=2024-08-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254749, encodeId=c3052254e4945, content=审稿速度:3.0<br>经验分享：7I是什么意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Wed Mar 05 18:10:41 CST 2025, time=2025-03-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2202091, encodeId=4ba42202091a9, content=4CX直接到7i是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ee74781933, createdName=gujianjun, createdTime=Mon May 06 22:51:00 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254635, encodeId=d6922254635b6, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：皮肤科;炎症<br>经验分享：2024-11-28 04:27:20 Manuscript submitted to Dove Medical Press<br>2024-12-10 14:10:57 Manuscript submitted to Journal of Inflammation Research <br>2024-12-24 00:40:42 Submission to Journal of Inflammation Research <br>2024-12-30 21:59:06 Manuscript Update Journal of Inflammation Research [Sub ID 509089]<br>2025-01-08 09:52:36 Your manuscript has been sent to the Editor-in-Chief <br>2025-01-21 18:26:52 Dove Medical Press - Confirmation of Revision Acceptance<br>2025-02-05 05:51:12 Your revised files have been successfully submitted<br>2025-02-19 22:08:16 Your corrected files have been successfully submitted [ID: 509089]<br>2025-02-26 16:49:58 Your manuscript has been sent to the Editor-in-Chief<br>2025-03-04 11:12:25 Dove Medical Press: Submission accepted for publication, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=013c8364030, createdName=ms9000000148815301, createdTime=Wed Mar 05 02:23:48 CST 2025, time=2025-03-05, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2254323, encodeId=c08f2254323e6, content=偏重的研究方向：炎症<br>经验分享：我想问一下大家二轮审稿是什么时候回来的呀？呜呜呜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Mon Mar 03 08:20:28 CST 2025, time=2025-03-03, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2247760, encodeId=14b7224e76081, content=审稿速度:1.0<br>偏重的研究方向：骨科<br>经验分享：投稿速度出奇的快，真是太震惊了，去年十月底投稿<br>1.10日就录用，总共经历了2两轮审稿，太给力了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:15:14 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251451, encodeId=3900225145188, content=偏重的研究方向：肿瘤<br>经验分享：请问4cr二轮审稿 多久会有结果呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Feb 11 14:00:04 CST 2025, time=2025-02-11, status=1, ipAttribution=上海)]
    2025-03-03 ms8000000556081062 来自加利福尼亚

    偏重的研究方向：炎症
    经验分享：我想问一下大家二轮审稿是什么时候回来的呀？呜呜呜

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2256447, encodeId=e067225644eb7, content= <br>1AB会持续多久 已经投稿半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dba02798280, createdName=luozf2013, createdTime=Mon Mar 17 15:16:58 CST 2025, time=昨天, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254847, encodeId=f383225484e2f, content=偏重的研究方向：免疫;炎症<br>经验分享：2g和2g x有啥区别？？2g x是拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19302219324, createdName=120f50f1m32(暂无昵称), createdTime=Thu Mar 06 12:03:22 CST 2025, time=2025-03-06, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2255761, encodeId=adac2255e6167, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：看了论坛好久，今天回馈给兄弟们一个时间线<br>12 December 2024 Peer review selection<br>13 December 2024 Peer review invitations sent<br>13 December 2024 First peer reviewer allocated<br>2 January 2025 First report returned<br>22 January 2025 Second or more peer reviewer reports returned<br>22 January 2025 Report sent to the Editor-in-Chief<br>24 January 2025 Report: revise with changes<br>31 January 2025 Resubmission pending<br>6 February 2025 Resubmitted manuscript received<br>13 February 2025 Query regarding revised manuscript<br>15 February 2025 Processing revised manuscript<br>21 February 2025 Sent to Editor-in-Chief for acceptance or rejection<br>21 February 2025 Peer reviewer(s) second round<br>3 March 2025 Peer reviewer(s) second round completed<br>March 2025 Accepted for publication, invoice sent<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9fa5603307, createdName=ms2000002102678296, createdTime=Wed Mar 12 16:28:46 CST 2025, time=2025-03-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218136, encodeId=09a322181369e, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：2024-03-12 submitted 之后一直1A_1<br>2024-04-04 变成了1A_2 然后继续没动静。。。<br>2024-05-02 收到编辑邮件让确认一篇团队刚发表的文章，说重复性高，回复后让添加到参考文献。<br>2024-05-06 重新提交后让每位作者确认利益冲突<br>2024-05-07 送审<br>2024-06-27 Report sent to the Editor-in-Chief<br>2024-07-02 Report: revise with changes 但是7-5才收到编辑让修稿及具体审稿意见的邮件<br>2024-07-19 Resubmitted manuscript received<br>2024-07-24 Sent to Editor-in-Chief for acceptance or rejection<br>2024-07-30 Accepted for publication, invoice sent<br>前期真的巨无敌慢！！！着急毕业的慎重。期间发了无数条邮件问，好在编辑回复的还算及时。<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e62d5561724, createdName=duanduan127, createdTime=Fri Aug 02 14:51:42 CST 2024, time=2024-08-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254749, encodeId=c3052254e4945, content=审稿速度:3.0<br>经验分享：7I是什么意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Wed Mar 05 18:10:41 CST 2025, time=2025-03-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2202091, encodeId=4ba42202091a9, content=4CX直接到7i是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ee74781933, createdName=gujianjun, createdTime=Mon May 06 22:51:00 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254635, encodeId=d6922254635b6, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：皮肤科;炎症<br>经验分享：2024-11-28 04:27:20 Manuscript submitted to Dove Medical Press<br>2024-12-10 14:10:57 Manuscript submitted to Journal of Inflammation Research <br>2024-12-24 00:40:42 Submission to Journal of Inflammation Research <br>2024-12-30 21:59:06 Manuscript Update Journal of Inflammation Research [Sub ID 509089]<br>2025-01-08 09:52:36 Your manuscript has been sent to the Editor-in-Chief <br>2025-01-21 18:26:52 Dove Medical Press - Confirmation of Revision Acceptance<br>2025-02-05 05:51:12 Your revised files have been successfully submitted<br>2025-02-19 22:08:16 Your corrected files have been successfully submitted [ID: 509089]<br>2025-02-26 16:49:58 Your manuscript has been sent to the Editor-in-Chief<br>2025-03-04 11:12:25 Dove Medical Press: Submission accepted for publication, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=013c8364030, createdName=ms9000000148815301, createdTime=Wed Mar 05 02:23:48 CST 2025, time=2025-03-05, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2254323, encodeId=c08f2254323e6, content=偏重的研究方向：炎症<br>经验分享：我想问一下大家二轮审稿是什么时候回来的呀？呜呜呜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Mon Mar 03 08:20:28 CST 2025, time=2025-03-03, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2247760, encodeId=14b7224e76081, content=审稿速度:1.0<br>偏重的研究方向：骨科<br>经验分享：投稿速度出奇的快，真是太震惊了，去年十月底投稿<br>1.10日就录用，总共经历了2两轮审稿，太给力了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:15:14 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251451, encodeId=3900225145188, content=偏重的研究方向：肿瘤<br>经验分享：请问4cr二轮审稿 多久会有结果呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Feb 11 14:00:04 CST 2025, time=2025-02-11, status=1, ipAttribution=上海)]
    2025-01-12 ms5000002977722138 来自上海

    审稿速度:1.0
    偏重的研究方向：骨科
    经验分享：投稿速度出奇的快，真是太震惊了，去年十月底投稿
    1.10日就录用，总共经历了2两轮审稿，太给力了。

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2256447, encodeId=e067225644eb7, content= <br>1AB会持续多久 已经投稿半个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dba02798280, createdName=luozf2013, createdTime=Mon Mar 17 15:16:58 CST 2025, time=昨天, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254847, encodeId=f383225484e2f, content=偏重的研究方向：免疫;炎症<br>经验分享：2g和2g x有啥区别？？2g x是拒稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19302219324, createdName=120f50f1m32(暂无昵称), createdTime=Thu Mar 06 12:03:22 CST 2025, time=2025-03-06, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2255761, encodeId=adac2255e6167, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：看了论坛好久，今天回馈给兄弟们一个时间线<br>12 December 2024 Peer review selection<br>13 December 2024 Peer review invitations sent<br>13 December 2024 First peer reviewer allocated<br>2 January 2025 First report returned<br>22 January 2025 Second or more peer reviewer reports returned<br>22 January 2025 Report sent to the Editor-in-Chief<br>24 January 2025 Report: revise with changes<br>31 January 2025 Resubmission pending<br>6 February 2025 Resubmitted manuscript received<br>13 February 2025 Query regarding revised manuscript<br>15 February 2025 Processing revised manuscript<br>21 February 2025 Sent to Editor-in-Chief for acceptance or rejection<br>21 February 2025 Peer reviewer(s) second round<br>3 March 2025 Peer reviewer(s) second round completed<br>March 2025 Accepted for publication, invoice sent<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9fa5603307, createdName=ms2000002102678296, createdTime=Wed Mar 12 16:28:46 CST 2025, time=2025-03-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218136, encodeId=09a322181369e, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：2024-03-12 submitted 之后一直1A_1<br>2024-04-04 变成了1A_2 然后继续没动静。。。<br>2024-05-02 收到编辑邮件让确认一篇团队刚发表的文章，说重复性高，回复后让添加到参考文献。<br>2024-05-06 重新提交后让每位作者确认利益冲突<br>2024-05-07 送审<br>2024-06-27 Report sent to the Editor-in-Chief<br>2024-07-02 Report: revise with changes 但是7-5才收到编辑让修稿及具体审稿意见的邮件<br>2024-07-19 Resubmitted manuscript received<br>2024-07-24 Sent to Editor-in-Chief for acceptance or rejection<br>2024-07-30 Accepted for publication, invoice sent<br>前期真的巨无敌慢！！！着急毕业的慎重。期间发了无数条邮件问，好在编辑回复的还算及时。<br><br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e62d5561724, createdName=duanduan127, createdTime=Fri Aug 02 14:51:42 CST 2024, time=2024-08-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254749, encodeId=c3052254e4945, content=审稿速度:3.0<br>经验分享：7I是什么意思啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Wed Mar 05 18:10:41 CST 2025, time=2025-03-05, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2202091, encodeId=4ba42202091a9, content=4CX直接到7i是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ee74781933, createdName=gujianjun, createdTime=Mon May 06 22:51:00 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2254635, encodeId=d6922254635b6, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：皮肤科;炎症<br>经验分享：2024-11-28 04:27:20 Manuscript submitted to Dove Medical Press<br>2024-12-10 14:10:57 Manuscript submitted to Journal of Inflammation Research <br>2024-12-24 00:40:42 Submission to Journal of Inflammation Research <br>2024-12-30 21:59:06 Manuscript Update Journal of Inflammation Research [Sub ID 509089]<br>2025-01-08 09:52:36 Your manuscript has been sent to the Editor-in-Chief <br>2025-01-21 18:26:52 Dove Medical Press - Confirmation of Revision Acceptance<br>2025-02-05 05:51:12 Your revised files have been successfully submitted<br>2025-02-19 22:08:16 Your corrected files have been successfully submitted [ID: 509089]<br>2025-02-26 16:49:58 Your manuscript has been sent to the Editor-in-Chief<br>2025-03-04 11:12:25 Dove Medical Press: Submission accepted for publication, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=013c8364030, createdName=ms9000000148815301, createdTime=Wed Mar 05 02:23:48 CST 2025, time=2025-03-05, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2254323, encodeId=c08f2254323e6, content=偏重的研究方向：炎症<br>经验分享：我想问一下大家二轮审稿是什么时候回来的呀？呜呜呜, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ba58345662, createdName=ms8000000556081062, createdTime=Mon Mar 03 08:20:28 CST 2025, time=2025-03-03, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=2247760, encodeId=14b7224e76081, content=审稿速度:1.0<br>偏重的研究方向：骨科<br>经验分享：投稿速度出奇的快，真是太震惊了，去年十月底投稿<br>1.10日就录用，总共经历了2两轮审稿，太给力了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:15:14 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251451, encodeId=3900225145188, content=偏重的研究方向：肿瘤<br>经验分享：请问4cr二轮审稿 多久会有结果呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ab5425857, createdName=Doctorfan, createdTime=Tue Feb 11 14:00:04 CST 2025, time=2025-02-11, status=1, ipAttribution=上海)]
    2025-02-11 Doctorfan 来自上海

    偏重的研究方向：肿瘤
    经验分享：请问4cr二轮审稿 多久会有结果呢

    1

    展开1条回复
共500条页码: 1/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分